Table 1.
Characteristics of included controlled trials.
| Study | Targets | Surgical modus | Subject size, n | Age (years) | Disease duration (years) | Outcome measure | Assessment time points |
|---|---|---|---|---|---|---|---|
| Anderson et al. (22) | STN | Bilateral | 12 | 61.0 ± 9.0 | 15.6 ± 5.0 | Dyskinesia severity rating | Baseline, 12 months |
| GPi | 11 | 54.0 ± 12.0 | 10.3 ± 2.0 | ||||
| Burchiel et al. (18) | STN | Bilateral | 6 | 62.8 ± 12.0 | 13.6 ± 5.0 | Dyskinesia severity rating | Baseline, 12 months |
| GPi | 4 | 46.5 ± 11.0 | 10.6 ± 2.0 | ||||
| Rodriguez-Oroz et al. (23) | STN | Bilateral | 49 | 59.8 ± 9.8 | 14.1 ± 5.9 | A dyskinesia scale | Baseline, 12 months 3-4y |
| GPi | 20 | 55.8 ± 9.4 | 14.4 ± 5.7 | LED | |||
| Odekerken et al. (16) | STN | Bilateral | 63 | 60.9 ± 7.6 | 12.0 ± 5.3 | CDRS | Baseline, 12 months |
| GPi | 65 | 59.1 ± 7.8 | 10.8 ± 4.2 | LED | |||
| Nutt et al. (24) | STN | Bilateral | 6 | 56.5 ± 15.1 | 9.5 ± 2.2 | Dyskinesia severity rating | Baseline, 12 months |
| GPi | 6 | 56.8 ± 11.5 | 19.5 ± 3.9 | ||||
| Follett et al. (17) | STN | Bilateral | 147 | 61.9 ± 8.7 | 11.1 ± 5.0 | Motor function with Dyskinesia LED | Baseline, 24months |
| GPi | 152 | 61.8 ± 8.7 | 11.5 ± 5.4 | ||||
| Weaver et al. (25) | STN | Bilateral | 70 | 60.7 ± 8.9 | 11.3 ± 4.7 | Motor function with Dyskinesia LED | Baseline, 6 months 24 month, 36 months |
| GPi | 89 | 60.4 ± 8.3 | 11.4 ± 4.9 | ||||
| Obeso et al. (26) | STN | Bilateral | 96 | 59.0 ± 9.6 | 44.6 ± 8.9 | Motor function with Dyskinesia LED | Baseline, 6 months |
| GPi | 38 | 55.7 ± 9.8 | 41.2 ± 9.5 |
CDRS, clinical dyskinesia rating scale; DBS, deep brain stimulation; GPi, globus pallidus interna; LED, levodopa equivalent doses; STN, subthalamic nucleus; UPDRS IV, unified Parkinson's disease rating scale IV.